Glyconics is a company at the forefront of diagnostic innovation, using infrared spectroscopy to analyse samples for markers of disease across a wide range of conditions.
4 million people globally will end up in hospital at a cost of £14bn. Using Infrared spectroscopy, our hand-held device can diagnose and predict days before when such acute attack will happen so saving time, money and lives. Our platform can be used for a wide range of acute and chronic conditions.
Glyconics are in the Business Weekly Top 50 Cambridge companies to watch and won EU awards and UK grants.